Oncology Venture receives approx. SEK 740 000 through exercise of warrants of series 2015/2018

Oncology Venture Sweden AB (”Oncology Venture”) announces that CFO Nikolaj Buhl Jensen has exercised 100 000 warrants of series 2015/2018, meaning that 107,000 shares are issued for a share price of SEK 6.88 per share. Oncology Venture thus receives SEK 740,000 through the exercise of warrants of series 2015/2018. A total of 70,000 warrants of series 2015/2018 remains in ”Optionsprogram 1” after the exercise of warrants by Nikolaj Buhl Jensen. The warrant terms concerning warrant exercising have been adjusted as a result of the rights issue that was conducted during the spring 2017, which activated a conversion of warrants of series 2015/2018.

Extraordinary general meeting in Oncology Venture on June 26th, 2015, decided to establish three warrant programs (”Optionsprogram 1-3”) for the company’s co-workers and board members. Optionsprogram 1 embraces a total of 170,000 warrants of series 2015/2018, of which CFO Nikolaj Buhl Jensen has received 100,000. Each warrant of series 2015/2018 entitles to subscription of 1.07 new share in Oncology Venture. Through the exercise of warrants of series 2015/2018, the share capital of Oncology Venture thus increases by SEK 14,980.00 through issuance of 107 000 shares, each with a share quota of SEK 0.14, for a subscription price of SEK 6.88 per share. The total issue amount is thus SEK 736,160.00. After registration at Bolagsverket (The Swedish Company Registration Office) the share capital will amount to SEK 1,552,260.22 and the amount of shares will amount to 11,087,573 shares.

The exercised warrants above will not be adjusted as a result of the right issue that is initiated on January 11th, 2018. The remaining outstanding warrants in Optionsprogram 1-3 will though be adjusted as a result of the upcoming rights issue, which activates a conversion of Optionsprogram 1-3 in accordance with decided warrant terms.

For further information, please contact

This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on January 8th, 2018.

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP® – in order to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.

Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates. OV-SPV 2 is a Danish company that shall test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor. Oncology Venture currently holds 92 percent of the shares in 2X Oncology Inc. and 40 percent of the shares in OV-SPV 2.